A89 Stock Overview
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Adocia SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.93 |
| 52 Week High | €15.72 |
| 52 Week Low | €2.77 |
| Beta | 0.85 |
| 1 Month Change | -4.92% |
| 3 Month Change | -24.48% |
| 1 Year Change | 184.74% |
| 3 Year Change | -12.38% |
| 5 Year Change | -55.25% |
| Change since IPO | -48.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| A89 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.7% | -0.2% | 0.5% |
| 1Y | 184.7% | -22.8% | 1.3% |
Return vs Industry: A89 exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: A89 exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| A89 volatility | |
|---|---|
| A89 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A89's share price has been volatile over the past 3 months.
Volatility Over Time: A89's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 97 | Olivier Soula | www.adocia.com |
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide.
Adocia SA Fundamentals Summary
| A89 fundamental statistics | |
|---|---|
| Market cap | €115.31m |
| Earnings (TTM) | -€20.54m |
| Revenue (TTM) | €10.84m |
10.6x
P/S Ratio-5.6x
P/E RatioIs A89 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A89 income statement (TTM) | |
|---|---|
| Revenue | €10.84m |
| Cost of Revenue | €25.30m |
| Gross Profit | -€14.46m |
| Other Expenses | €6.09m |
| Earnings | -€20.54m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -1.44 |
| Gross Margin | -133.32% |
| Net Profit Margin | -189.46% |
| Debt/Equity Ratio | -119.7% |
How did A89 perform over the long term?
See historical performance and comparison